Abstract
Transcatheter interventions for structural heart disease represent an emerging field in interventional cardiology. Undoubtedly, there is an absolute necessity for antiplatelet and/or anticoagulation treatment prior, during and post such interventions. However, currently administered regimens are mainly based in expert consensus recommendations. In the present review we aim to summarize data regarding anti platelet and/or anticoagulation treatment in the following transcatheter structural heart interventions: left atrial appendage closure, atrial septal defect closure, patent foramen oval closure, paravalvular leak closure.
Keywords: ASD, LAA, PFO, transcatheter, warfarin, coumadin, antiplatelet, NOAC.
Current Pharmaceutical Design
Title:Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI
Volume: 23 Issue: 9
Author(s): Manolis Vavuranakis*, Konstantinos Dean Boudoulas, Ourania Katsarou, Dimitrios A. Vrachatis, Konstantinos I. Kalogeras, Theodore G. Papaioannou, Gerasimos Siasos, Evangelos Oikonomou, George Lazaros, Michael-Andreas Vavuranakis, Spyridon Deftereos and Dimitrios Tousoulis
Affiliation:
- 13 Astypaleas, Anoixi, Attiki 14569,Greece
Keywords: ASD, LAA, PFO, transcatheter, warfarin, coumadin, antiplatelet, NOAC.
Abstract: Transcatheter interventions for structural heart disease represent an emerging field in interventional cardiology. Undoubtedly, there is an absolute necessity for antiplatelet and/or anticoagulation treatment prior, during and post such interventions. However, currently administered regimens are mainly based in expert consensus recommendations. In the present review we aim to summarize data regarding anti platelet and/or anticoagulation treatment in the following transcatheter structural heart interventions: left atrial appendage closure, atrial septal defect closure, patent foramen oval closure, paravalvular leak closure.
Export Options
About this article
Cite this article as:
Vavuranakis Manolis*, Boudoulas Dean Konstantinos, Katsarou Ourania, Vrachatis A. Dimitrios, Kalogeras I. Konstantinos, Papaioannou G. Theodore, Siasos Gerasimos, Oikonomou Evangelos, Lazaros George, Vavuranakis Michael-Andreas, Deftereos Spyridon and Tousoulis Dimitrios, Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161221143416
DOI https://dx.doi.org/10.2174/1381612822666161221143416 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Drugs Targeting Atherosclerosis: Current and Emerging Approaches (Executive Editors: Vangelis G. Manolopoulos and Anna Tavridou)]
Current Pharmaceutical Design Frequencies of Single Nucleotide Polymorphisms in Cytochrome P450 Genes (CYP1A2, 2A6, 2B6, 3A4 and 3A5) in a Rwandan Population: Difference to Other African Populations
Current Pharmacogenomics and Personalized Medicine Do We Need More Research on Platelet Function in South Asian Immigrants?
Inflammation & Allergy - Drug Targets (Discontinued) Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride
Anti-Infective Agents Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Nothing But Stress – The Interplay of Angiotensin II, Inflammation, Hypertension and Atherosclerosis: Implications for Atherosclerotic Plaque Stability
Vascular Disease Prevention (Discontinued) Q Fever Endocarditis
Infectious Disorders - Drug Targets Therapeutic Targeting of HDL and Reverse Cholesterol Transport
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice
Current Drug Safety The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Anticoagulation in Patients with Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Efficacy and Safety of Combined Radiotherapy with EGFR Inhibitors and Chemotherapy for Laryngeal Organ Preservation in Patients with Locally Advanced Hypopharyngeal Carcinomas
Current Cancer Drug Targets Tissue Doppler Imaging in Coronary Heart Diseases and Heart Failure: An Up to Date
Recent Patents on Medical Imaging Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) HbA1c, Fructosamine, and Glycated Albumin in the Detection of Dysglycaemic Conditions
Current Diabetes Reviews A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Target Oxygen Levels and Critical Care of the Newborn
Current Pediatric Reviews Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design